Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

References

• European Society for Medical Oncology. ESMO statements for vaccination against COVID-19 in patients with cancer. 2021. https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination
   Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Choueiri TK, Shah DP, et al. COVID-19 and cancer consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–1918.
   PubMed Web of Science ®Google Scholar
• Piñana JL, Martino R, García-García I, Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH), et al. Infectious complications subcommittee of the Spanish hematopoietic stem cell transplantation and cell therapy group (GETH). risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9(1):21.
   PubMed Web of Science ®Google Scholar
• García-Suárez J, de la Cruz J, Cedillo Á, the Asociación Madrileña de Hematología y Hemoterapia (AMHH), et al. Asociación madrileña de hematología y hemoterapia (AMHH). impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133.
   PubMed Web of Science ®Google Scholar
• Muntañola A, Villacampa G, Hernández-Rivas JA, of the GELLC (Grupo Español de Leucemia Linfática Crónica), et al. Of the GELLC (grupo español de leucemia linfática crónica). clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Exp Hematol Oncol. 2020;9(1):37.
   PubMed Web of Science ®Google Scholar
• Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(6):E393–E393.
   Web of Science ®Google Scholar
• Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586–2588.
   PubMed Web of Science ®Google Scholar
• https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_es.
   Google Scholar
• https://ec.europa.eu/commission/presscorner/detail/en/STATEMENT_20_2510.
   Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. C4591001 clinical trial group safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al.; For the COVE study group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384:403–416.
   PubMed Web of Science ®Google Scholar
• Maneikis K, Šablauskas K, Ringelevičiūtė U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):S2352-3026(21)00169–1.
   Web of Science ®Google Scholar
• Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021;96(10):1195–1203.
   PubMed Web of Science ®Google Scholar
• Redjoul R L, Bouter A, Beckerich F, et al. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet. 2021;398(10297):298–299.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173.
   PubMed Web of Science ®Google Scholar
• Ali H, Ngo D, Aribi A, et al. Safety and tolerability of SARS-CoV-2 Emergency-Use authorized vaccines allogeneic hematopoietic stem cell transplant recipients. Transplant Cell Ther. 2021;S2666-6367(21)01073–3.
   Google Scholar
• Greenberger LM, Saltzman LA, Senefeld JW, et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cel. 2021;39(8):1031–1033.
   PubMed Web of Science ®Google Scholar
• Avivi I, Balaban R, Shragai T, et al. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol. 2021;195(2):186–193.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Cesaro S, de Lavallade H, et al. European Conference on Infections in Leukaemia group. Vaccination of patients with hematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e188–e199.
   Google Scholar
• Cordonnier C, Einarsdottir S, Cesaro S, et al. European Conference on Infections in Leukaemia group. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e200–e212.
   Google Scholar
• Pandit A, Leblebjian H, Hammond SP, et al. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2018; 53(7):942–945.
   PubMed Web of Science ®Google Scholar
• Palazzo M, Shah GL, Copelan O, et al. Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance. Biol Blood Marrow Transplant. 2018;24(4):871–876.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Boccadoro M, Moreau P, et al. Recommendations for vaccination in multiple myeloma: a consensus of the european myeloma network. Leukemia. 2021;35(1):31–44.
   PubMed Web of Science ®Google Scholar
• Cherif H, Hoglund M, Pauksens K. Adjuvanted influenza A (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients. Eur J Haematol. 2013;90(5):413–419.
   PubMed Web of Science ®Google Scholar
• Hahn M, Schnitzler P, Schweiger B, et al. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica. 2015;100(7):e285–88.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96(2):307–314.
   PubMed Web of Science ®Google Scholar
• Branagan AR, Duffy E, Gan G, et al. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Adv. 2021;5(5):1535–1539.
   PubMed Web of Science ®Google Scholar
• Croce E, Hatz C, Jonker EF, et al. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation—a systematic review of randomized trials, observational studies and case reports. Vaccine. 2017; 35:1216–1226.
   PubMed Web of Science ®Google Scholar
• Auletta J, Chemaly R, Khawaja F, et al. ASH-ASTCT COVID-19 and vaccines: frequently asked questions. 2021. p. 2–5.
   Google Scholar
• https://ehaweb.org/covid-19/eha-statement-on-covid-19-vaccines/recommendations-for-covid-19-vaccination-in-patients-with-hematologic-cancer/.
   Google Scholar
• https://www.prnewswire.com/news-releases/nccn-shares-new-guidance-principles-for-vaccinating-people-with-cancer-against-covid-19-301213154.html.
   Google Scholar
• https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients#.YBSMwV99dh9.twitter.
   Google Scholar
• Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–e94.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395–400.
   PubMed Web of Science ®Google Scholar
• Valdivia A, Torres I, Latorre V, et al. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. Eur J Clin Microbiol Infect Dis. 2021;40(3):485–494.
   PubMed Web of Science ®Google Scholar
• Ljungman P, De La Camara R, Mikulska M, et al. COVID-19 and stem cell transplantation; results from the prospective survey by the infectious diseases working party of the european society for blood and marrow transplantation (EBMT) and the spanish hematopoietic stem cell transplantation and cell therapy group (GETH). Blood. 2020; 136(Supplement 1):32–33.
   Google Scholar
• Avetisyan G, Aschan J, Hassan M, et al. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation. 2008;86(2):257–263.
   PubMed Web of Science ®Google Scholar
• Piñana JL, Pérez A, Montoro J, et al. Clinical effectiveness of influenza vaccination after allogeneic hematopoietic stem cell transplantation: a cross-sectional, prospective, observational study. Clin Infect Dis. 2019;68(11):1894–1903.
   PubMed Web of Science ®Google Scholar
• https://www.ebmt.org/sites/default/files/2020-12/COVID%20vaccines%20version%202.03%20with%20table.pdf.
   Google Scholar
• Hu Y, Tan Su Yin E, Yang Y, et al. CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. Curr Res Transl Med. 2020;68(3):111–118.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Mikulska M, De la Camara R, European Society for Blood and Marrow Transplantation, et al. For the european society for blood and marrow transplantation. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020;55(11):2071–2076.
   PubMed Web of Science ®Google Scholar
• Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021;49(2):215–231.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Zappasodi P, Roncoroni E, et al. Impact of covid-19 on the treatment of acute myeloid leukemia. Leukemia. 2020;34(8):2254–2256.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cattaneo C, Arcaini L, ITA-HEMA-COV Investigators, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745.
   PubMed Web of Science ®Google Scholar
• Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and Meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892.
   PubMed Web of Science ®Google Scholar
• Palanques-Pastor T, Megías-Vericat JE, Martínez P, et al. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. Leuk Lymphoma. 2021;22:1–11.
   Google Scholar
• O’Nions J, Muir L, Zheng J, et al. SARS-CoV-2 antibody responses in patients with acute leukaemia. Leukemia. 2021;35(1):289–292.
   PubMed Web of Science ®Google Scholar
• Foà R, Bonifacio M, Chiaretti S, et al. Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a campus ALL study. Br J Haematol. 2020;190(1):e3–e5.
   PubMed Web of Science ®Google Scholar
• Martínez-López J, Mateos MV, Encinas C, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10(10):103.
   PubMed Web of Science ®Google Scholar
• Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the international myeloma society data set. Blood. 2020;136(26):3033–3040.
   PubMed Web of Science ®Google Scholar
• Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000;82(7):1261–1265.
   PubMed Web of Science ®Google Scholar
• Noonan K, Rudraraju L, Ferguson A, et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012;18(5):1426–1434.
   PubMed Web of Science ®Google Scholar
• Tormo M, Díaz Beyá M, Gil A, et al. Estudio de la incidencia y características de la infección por COVID-19 en pacientes con SMD incluidos en el registro del Grupo Español de Síndromes Mielodisplásicos (GESMD). Thrombosis and Haemostasis. International Journal for Vascular Biology and Medicine. XXXXVI Congreso nacional de la Sociedad Española de Trombosis y Hemostasia. CO-217. 2020.
   Google Scholar
• Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145–153.
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Infectious Diseases Society of America, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100.
   PubMed Web of Science ®Google Scholar
• Douglas AP, Trubiano JA, Barr I, et al. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;102(10):e397–e9.
   PubMed Web of Science ®Google Scholar
• Pleyer C, Ali MA, Cohen JI, et al. Effect of bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185–189.
   PubMed Web of Science ®Google Scholar
• Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–1143.
   PubMed Web of Science ®Google Scholar
• Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the european research initiative on CLL, and CLL campus. Leukemia. 2020;34(9):2354–2363.
   PubMed Web of Science ®Google Scholar
• Shadman M, Ujjani C. Vaccinations in CLL: implications for COVID-19. Blood. 2021;137(2):144–146.
   PubMed Web of Science ®Google Scholar
• Sun C, Gao J, Couzens L, et al. Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. JAMA Oncol. 2016;2(12):1656–1657.
   PubMed Web of Science ®Google Scholar
• Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH research collaborative data hub. Blood Adv. 2020;4(23):5966–5975.
   PubMed Web of Science ®Google Scholar
• Shree T, Li Q, Glaser SL, et al. Impaired immune health in survivors of diffuse large B-Cell lymphoma. J Clin Oncol. 2020;38(15):1664–1675.
   PubMed Web of Science ®Google Scholar
• Regalado I, Jiménez-Ubieto A, Hernández-Rivas JA, et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere. 2021;5(3):e538.
   PubMed Web of Science ®Google Scholar
• Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769–6771.
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Alvarez-Larran A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021;35(2):485–493.
   PubMed Web of Science ®Google Scholar
• Barbui T, De Stefano V, Alvarez-Larran A, et al. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021;11(2):21.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122(2):227–238.
   PubMed Web of Science ®Google Scholar
• Harrington P, Harrison CN, Dillon R, et al. Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Br J Haematol. 2021;193(4):692–696.
   PubMed Web of Science ®Google Scholar
• Giannetti MP, Weller E, Alvarez-Twose I, et al. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. J Allergy Clin Immunol Pract. 2021;9(5):2083–2086. doi:10.1016/j.jaip.2021.02.023.
   Google Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–438.
   PubMed Web of Science ®Google Scholar
• Vigón L, Rodríguez-Mora S, Luna A, et al. Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochem Pharmacol. 2020;182:114203.
   PubMed Web of Science ®Google Scholar
• Casajuana J, Iglesias B, Fàbregas M, et al. Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-Centre randomized controlled clinical trial. BMC Blood Disord. 20088:1.
   PubMedGoogle Scholar
• Chen PW, Tsai ZY, Chao TH, et al. Addressing vaccine-induced immune thrombotic thrombocytopenia (VITT) following COVID-19 vaccination: a mini-review of practical strategies. Acta Cardiol Sin. 2021;37(4):355–364.
   PubMed Web of Science ®Google Scholar